ILCOR guidelines recommend Target Temperature Management (TTM) to between 32°C and 36°C after
out-of-hospital cardiac arrest, based on low quality evidence. In a previous trial, TTM at
33°C did not confer a survival benefit or improved neurological function, compared to TTM at
36°C. A lower target temperature might be beneficial compared with normothermia and early
treatment of fever. Therefore the primary purpose of the TTM2-trial will be to study any
differences in mortality, neurological function and quality of life between a target
temperature of 33°C and standard care avoiding fever.